Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) CEO Adrian Adams acquired 500,000 shares of the stock in a transaction dated Wednesday, March 15th. The stock was purchased at an average cost of $2.46 per share, with a total value of $1,230,000.00. Following the purchase, the chief executive officer now directly owns 3,569,230 shares of the company’s stock, valued at $8,780,305.80. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) opened at 2.36 on Tuesday. The stock has a 50 day moving average price of $3.88 and a 200 day moving average price of $4.58. The firm’s market cap is $154.58 million. Aralez Pharmaceuticals Inc has a 1-year low of $2.05 and a 1-year high of $6.80.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last issued its quarterly earnings results on Monday, March 13th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.26) by $0.11. The business had revenue of $20 million for the quarter, compared to the consensus estimate of $21.86 million. Aralez Pharmaceuticals had a negative net margin of 211.76% and a negative return on equity of 65.67%. The business’s revenue was up 233.3% compared to the same quarter last year. During the same quarter last year, the business posted ($0.40) EPS. On average, analysts anticipate that Aralez Pharmaceuticals Inc will post ($1.07) EPS for the current year.
var userip;Your IP Address: document.write(userip);
Separately, Chardan Capital lowered their price objective on Aralez Pharmaceuticals from $10.00 to $5.50 and set a “buy” rating for the company in a research note on Wednesday, March 15th.
Hedge funds have recently modified their holdings of the stock. Norges Bank acquired a new stake in shares of Aralez Pharmaceuticals during the fourth quarter worth about $665,000. Armistice Capital LLC increased its stake in shares of Aralez Pharmaceuticals by 35.0% in the fourth quarter. Armistice Capital LLC now owns 2,836,000 shares of the company’s stock worth $12,507,000 after buying an additional 736,000 shares during the period. Glacier Peak Capital LLC increased its stake in shares of Aralez Pharmaceuticals by 122.6% in the fourth quarter. Glacier Peak Capital LLC now owns 102,400 shares of the company’s stock worth $452,000 after buying an additional 56,400 shares during the period. JW Asset Management LLC increased its stake in shares of Aralez Pharmaceuticals by 2.5% in the fourth quarter. JW Asset Management LLC now owns 2,680,140 shares of the company’s stock worth $11,820,000 after buying an additional 65,000 shares during the period. Finally, Tiger Legatus Capital Management LLC increased its stake in shares of Aralez Pharmaceuticals by 1.3% in the fourth quarter. Tiger Legatus Capital Management LLC now owns 1,985,000 shares of the company’s stock worth $8,754,000 after buying an additional 25,000 shares during the period. Hedge funds and other institutional investors own 44.01% of the company’s stock.
Aralez Pharmaceuticals Company Profile
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Ratings for Aralez Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.